{"id":34378,"date":"2018-01-24T11:23:09","date_gmt":"2018-01-24T10:23:09","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=34378"},"modified":"2018-01-24T11:54:27","modified_gmt":"2018-01-24T10:54:27","slug":"farmaci-nel-2017-ema-raccomanda-limmissione-commercio-92-nuovi-medicinali-uso-umano","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-nel-2017-ema-raccomanda-limmissione-commercio-92-nuovi-medicinali-uso-umano\/","title":{"rendered":"Medicines, in 2017 Ema recommended the placing on the market of 92 new medicines for human use"},"content":{"rendered":"<p>Rome, 24 January - In 2017, the European Medicines Agency (EMA) recommended 92 medicines for marketing authorisation. Of these, 35 had a new active substance, never before authorized in the European Union. Many of these medicines represent significant improvements in their therapeutic areas. The list of new drugs includes medicines for children, for rare diseases and advanced therapies.<\/p>\n<p>It is the summary of the activity conducted last year by the EMA, made known by the community agency itself, which - recalls a launch of <em>Public Policy<\/em> \u2013 published an overview of its key 2017 recommendations regarding the authorization of new medicines and the monitoring of the safety of medicines.<\/p>\n<p><em>\u201cProgress in the authorization of medicines<\/em> \u2013 says the Agency \u2013 <em>they are essential for public health as they can improve the treatment of diseases\u201d.<\/em><\/p>\n<p><a href=\"http:\/\/www.rifday.it\/2018\/01\/24\/farmaci-nel-2017-ema-via-libera-92-nuovi-medicinali-uso-umano\/\" target=\"_blank\" rel=\"noopener\">Ref Day \u2013 01\/24\/2018<\/a><\/p>\n<p>Related news: <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2018\/01\/WC500242079.pdf\" target=\"_blank\" rel=\"noopener\">EMA. Human medicines highlights 2017<\/a><\/p>\n<p id=\"page-title\"><a href=\"http:\/\/www.agenziafarmaco.gov.it\/content\/un-medicinale-orfano-\u00e8-ancora-tale-quando-raggiunge-il-mercato-ema-rende-pubbliche-le-valuta\" target=\"_blank\" rel=\"noopener\">Is an orphan drug still an orphan drug when it reaches the market? EMA makes public the assessments of the Committee for Orphan Drugs (COMP)<\/a><\/p>\n<p><a href=\"http:\/\/www.fimmg.org\/index.php?action=pages&amp;m=view&amp;p=18&amp;art=2527\" target=\"_blank\" rel=\"noopener\">Drugs, EU Court: Roche-Novartis agreement illegitimate and anti-competitive<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Roma, 24 gennaio \u2013\u00a0 Nel 2017, l\u2019Agenzia europea dei medicinali (Ema) ha raccomandato 92 medicinali per l\u2019autorizzazione all\u2019immissione in commercio. Di questi, 35 avevano una nuova sostanza attiva, mai autorizzata prima nell\u2019Unione europea. Molte di queste medicine rappresentano un significativo miglioramento nelle loro aree terapeutiche. La lista dei nuovi farmaci \u00a0comprende medicine per bambini, per &hellip;<\/p>","protected":false},"author":4,"featured_media":31244,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49],"class_list":["post-34378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=34378"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/31244"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=34378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=34378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=34378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}